PubMed HealthSearch

PubMed · 3555103

Antigenic differences between human platelets and megakaryocytes.

Abstract

To investigate the apparent paradox in the observation that most patients with immune thrombocytopenias have normal or increased numbers of megakaryocytes (MKs), the extent of antigenic cross-reactivity between normal platelets and MK was examined. Indirect immunofluorescence and ultrastructural studies were carried out by means of four antisera specific for platelets: anti-GpIb, anti-GpIIb/IIIa, anti-PLA1, and an antiserum from a patient with quinidine-induced thrombocytopenia. Following incubation of freshly collected marrow with these antisera, MK were first identified by phase-contrast microscopy and then inspected for fluorescence. Almost all MKs were found reactive with the last three antisera, albeit to a variable extent. In contrast, only 24% reacted with anti-GpIb. The pattern of fluorescence, ie, rim, partial or cytoplasmic, appeared to be related to the extent of MK fragmentation. Only rim fluorescence of living MKs could be interpreted to indicate that the platelet epitope was exposed on the surface of the precursor cell. The observations suggest that platelet antigens are variably expressed on the plasma membranes of MKs. In a clinical setting, the heterogeneity among platelet target antigens and the extent to which these are exposed on MKs at various stages of maturation may dictate the severity of the thrombocytopenia and degree of ineffective thrombocytopoiesis.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Hyde, D Zucker-Franklin. 1987. Antigenic differences between human platelets and megakaryocytes.. https://pubmed.ncbi.nlm.nih.gov/3555103/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Leucine33-proline33 substitution in human platelet glycoprotein IIIa determines HLA-DRw52a (Dw24) association of the immune response against HPA-1a (Zwa/PIA1) and HPA-1b (Zwb/PIA2).

Alloantibody formation against HPA-1a (Zwa/PIA1) has, to date, only been found in HLA-DRw52(a+) (Dw24) individuals. Alloimmunization against the product of the other HPA-1 allele, HPA-1b, is rare. We have been able to evaluate ten cases of HPA-1b alloimmunization in Europe in order to study whether there is an association between HLA phenotype and anti-HPA-1b antibody formation. HLA typing of these patients was performed with particular attention to the DRw52a specificity using specific T-cell clones. No association with DRw52a or any other known HLA phenotype was found. This finding implies that the amino acid substitution leucine33-proline33 in GPIIIa, responsible for HPA-1a/b, is of primary importance for the association of anti-HPA-1a antibody formation with DRw52a. These data show that the amino acid polymorphism affects the presentation of the immunogenic oligopeptides of HPA-1a and -1b in the HLA class-II groove.

Antigens, Human Platelet

Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy.

Neonatal thrombocytopenia affects 20-40% of the infants in intensive care units. The frequency of neonatal alloimmune thrombocytopenia (NAIT) is estimated at 1/1500 to 1/5000 live births. The risk of morbidity is significant with 20% neurological sequelae and the death rate is estimated at 10% of affected infants. During recent years considerable efforts have been made to prevent fetal bleeding and to avoid birth trauma, which have significantly changed the natural history of NAIT.

Antigens, Human Platelet

Self help for platelet serologists: the Australian Platelet Antibody Workshops.

The first three Australian Platelet Antibody Workshops (APAW) were held under the auspices of the Australasian Society of Blood Transfusion (ASBT) in 1989, 1990 and 1991. Participants submitted serum samples to the convenor who coded and distributed samples to laboratories routinely performing platelet serology. Results were summarized and discussed at the annual ASBT meetings. This report documents the evolution of platelet antibody tests in Australia and demonstrates the marked improvements in the participants' ability to differentiate platelet-specific antibodies from HLA antibodies and to identify the alloantigenic specificity of platelet antibodies. Five reference laboratories in Australia now hold panels typed for at least three platelet alloantigens.

Antigens, Human Platelet